Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Acceleron Pharma Files Registration Statement for Proposed Initial Public Offering
Acceleron Pharma, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.
Citigroup and Leerink Swann LLC will act as joint book-running managers for the offering. Piper Jaffray & Co. will act as lead manager and JMP Securities will act as co-manager for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by email at batprospectusdept@citi.com, or by phone at 800-831-9146; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-ß) protein superfamily, a large and diverse group of molecules that regulate the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated numerous innovative biologic therapies with novel mechanisms of action. These differentiated biologic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
Contact:
Acceleron Pharma
Tracey Murphy, 617-649-9328
Senior Director, Corporate Development
or
Media
Suda Communications LLC
Maureen L. Suda, 585-387-9248
Help employers find you! Check out all the jobs and post your resume.
Acceleron Pharma Files Registration Statement for Proposed Initial Public Offering
Acceleron Pharma, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.
Citigroup and Leerink Swann LLC will act as joint book-running managers for the offering. Piper Jaffray & Co. will act as lead manager and JMP Securities will act as co-manager for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by email at batprospectusdept@citi.com, or by phone at 800-831-9146; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-ß) protein superfamily, a large and diverse group of molecules that regulate the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated numerous innovative biologic therapies with novel mechanisms of action. These differentiated biologic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
Contact:
Acceleron Pharma
Tracey Murphy, 617-649-9328
Senior Director, Corporate Development
or
Media
Suda Communications LLC
Maureen L. Suda, 585-387-9248
Help employers find you! Check out all the jobs and post your resume.
